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British Menopause Society Factsheet
HIV and the menopause  
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Introduction
Over the past two decades, antiretroviral therapy (ART) has transformed HIV into a long-term 
condition with normal life expectancy for people stable on treatment.  
In 2016, 10,350 women living with HIV aged 45-56 (the age when women usually go through the 
menopause) attended HIV clinics in the UK. This is nearly half of all women attending for HIV care in 
the UK, and is five times the number in 20061.
As the number of women living with HIV reaching their midlife grows, we are beginning to 
understand the importance of addressing their healthcare needs during the menopause.  
What is the impact of the menopause on women living with 
HIV?
 The menopause transition can have multi-dimensional impacts on the health and well-being 
of women living with HIV.
 There is conflicting evidence on the association between HIV and earlier age at menopause2.
 HIV infection is associated with an elevated risk of osteoporosis and cardiovascular disease, 
both of which are particularly increased among postmenopausal women living with HIV3,4.
 Women living with HIV aged 45-60 are more likely to report sexual problems than their HIV-
negative counterparts1.
 Women living with HIV aged 45-60 report high levels of menopausal symptoms including hot 
flushes, urogenital symptoms, and psychological symptoms1.  
 Women living with HIV may find it hard to distinguish HIV-related symptoms from 
menopausal symptoms, leading to anxiety1.  
 Among women living with HIV, menopausal symptoms are associated with psychological 
distress1 and decreased adherence to ART (which is important in terms of women’s own 
health, and also the prevention of HIV transmission to others)5.
 Use of systemic and topical hormone replacement therapy (HRT) is very low among women 
living with HIV (8% and 3% respectively) despite the high prevalence of symptoms1.






























































What are the key points about managing the menopause in 
women living with HIV?  
 National HIV guidelines recommend baseline assessment of menstrual cycle within HIV 
clinics, and annual review thereafter, as well as assessment of menopausal symptoms in 
those aged >45 (or those assessed as being postmenopausal).
 As in women without HIV, laboratory investigations (such as follicle-stimulating hormone, 
FSH) are not routinely indicated in women living with HIV aged over 45 years with menstrual 
irregularity and/or vasomotor symptoms, especially if a woman has well-controlled HIV on 
ART.
 The majority of women living with HIV with menopausal symptoms can be managed in 
general practice (as is the case for women without HIV), with liaison with a woman’s HIV 
clinician.
 Management of menopause in women living with HIV should be informed by NICE guidelines 
on menopause.  
 HRT (either systemic or topical) are not contraindicated in HIV.
 The use of transdermal HRT is preferred in women living HIV due to the lower risk of 
gastrointestinal side effects and thromboembolic events.
 There may be drug interactions between systemic HRT and some ART regimens.  This can 
result in increased progestogen and reduced oestrogen levels, necessitating HRT dose 
titration.  HIV clinics and the Liverpool Drug Interactions website are good sources of 
information.
What support do women living with HIV need through the 
menopause?
 Nearly half of women living with HIV in a recent national study stated they did not have 
enough information about the menopause, leaving many feeling under-prepared1.
 Midlife women living with HIV should be provided information on menopause and symptom 
management (see resources for HIV specific leaflets).
 Research has found that peer-support (support from other women living with HIV) can help 
women during the menopause transition.  This may be accessed via local third sector 
organisations or HIV clinics1.
Resources
For healthcare providers:
BHIVA/BASHH/FSRH guidelines for the sexual & reproductive health of people living with HIV (draft): 
http://www.bhiva.org/documents/Guidelines/SRH/Consultations/SRH-guidelines-for-consultation-
2017.pdf 
Liverpool HIV Drug Interactions HRT chart: https://liverpool-hiv-
hep.s3.amazonaws.com/prescribing_resources/pdfs/000/000/028/original/TS_HRT_2017_Nov.pdf?
1520609847   
www.thebms.org.uk 
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